NCT00257465View on ClinicalTrials.gov

Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Melanoma
Interventions
BIOLOGICAL

Autologous, DNP-modified vaccine (M-Vax)

5.0, 2.5, 0.5, or 0 cells

BIOLOGICAL

Autologous, DNP-Modified Melanoma Vaccine

5 million cells

BIOLOGICAL

Autologous, DNP-Modified Vaccine

2.5 million cells

BIOLOGICAL

Autologous, DNP-Modified Vaccine

0.5 million cells

BIOLOGICAL

Autologous, DNP-Modified Vaccine

0 cells

Trial Locations (7)

19104

Hospital of the University of Pennsylvania, Philadelphia

19107

Thomas Jefferson University, Philadelphia

60612

University of Illinois School of Medicine, Chicago

77030

MD Anderson Cancer Center, Houston

92024

Pacific Oncology and Hematology Associates, San Diego

Unknown

University of Arizona Cancer Center, Tucson

University of Louisville, Louisville

Sponsors

Lead Sponsor

AVAX Technologies
All Listed Sponsors
lead

AVAX Technologies

INDUSTRY

NCT00257465 - Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma | Biotech Hunter | Biotech Hunter